Asthma therapy with agents preventing leukotriene synthesis or action.
Elucidation of the biochemistry of leukotriene production and the pharmacology of its actions has led to the development of a number of therapeutic agents shown to be of value in the treatment of asthma. These agents either prevent the synthesis of the leukotrienes, by preventing the action of the 5-lipoxygenase-activating protein or the catalytic action of the 5-lipoxygenase, or by inhibiting the action of leukotrienes at the CysLT1 receptor. Numerous clinical trials in exercise-induced asthma, allergen-induced asthma, aspirin-induced asthma, and spontaneously occurring asthmatic episodes have indicated that these agents are safe and effective asthma treatments.
Drazen
J M
JM
Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA.
D000085:Acetates / Q000494:pharmacology / Q000627:therapeutic use; D000485:Allergens / Q000009:adverse effects; D018927:Anti-Asthmatic Agents / Q000145:classification / Q000494:pharmacology / Q000627:therapeutic use*; D001094:Arachidonate 5-Lipoxygenase / Q000502:physiology; D016718:Arachidonic Acid / Q000378:metabolism; D001241:Aspirin / Q000009:adverse effects; D001249:Asthma / Q000188:drug therapy* / Q000209:etiology / Q000378:metabolism; D001250:Asthma, Exercise-Induced / Q000188:drug therapy / Q000378:metabolism; D016084:Bronchoconstriction / Q000187:drug effects; D002867:Chromones / Q000494:pharmacology / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003521:Cyclopropanes; D004311:Double-Blind Method; D006801:Humans; D006918:Hydroxyurea / Q000031:analogs & derivatives / Q000494:pharmacology / Q000627:therapeutic use; D007211:Indoles; D020024:Leukotriene Antagonists / Q000494:pharmacology / Q000627:therapeutic use*; D015289:Leukotrienes / Q000096:biosynthesis*; D016859:Lipoxygenase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D008563:Membrane Lipids / Q000378:metabolism; D008565:Membrane Proteins; D048448:Phenylcarbamates; D010741:Phospholipases A / Q000378:metabolism; D011804:Quinolines / Q000494:pharmacology / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D018077:Receptors, Leukotriene; D012449:Safety; D013440:Sulfides; D013449:Sulfonamides; D014105:Tosyl Compounds / Q000494:pharmacology / Q000627:therapeutic use
D000085:Acetates; D000485:Allergens; D018927:Anti-Asthmatic Agents; D002867:Chromones; D003521:Cyclopropanes; D007211:Indoles; D020024:Leukotriene Antagonists; D015289:Leukotrienes; D016859:Lipoxygenase Inhibitors; D008563:Membrane Lipids; D008565:Membrane Proteins; D048448:Phenylcarbamates; D011804:Quinolines; D018077:Receptors, Leukotriene; D013440:Sulfides; D013449:Sulfonamides; D014105:Tosyl Compounds; D016718:Arachidonic Acid; C412375:cysteinyl leukotriene receptor 2; D001094:Arachidonate 5-Lipoxygenase; D010741:Phospholipases A; C083169:leukotriene D4 receptor; C093875:montelukast; D001241:Aspirin; C047681:pranlukast; C063449:zileuton; D006918:Hydroxyurea; C062735:zafirlukast